Coronary No-reflow Phenomenon: A Review of Therapeutic Pharmacological Agents

Shahri, Bahram; Vojdanparast, Mohammad

doi:10.30483/rijm.2020.254145.1002

Coronary No-reflow Phenomenon: A Review of Therapeutic Pharmacological Agents

Document Type : Original Article

Authors

¹ Department of Cardiovascular Diseases, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

² Cardiology Department, Razavi Hospital, Imam Reza International University, Mashhad, Iran

10.30483/rijm.2020.254145.1002

Abstract

Coronary no-reflow phenomenon (CNRP) is one of the leading catastrophic consequences of percutaneous coronary intervention (PCI). Although several preventive strategies have been advised, yet CNRP is not entirely controlled with pharmacological agents after diag- nosis. This study is a review of therapeutic pharmacological agents used in various studies for post-PCI-CNRP. Several pharmacologi- cal agents have been introduced for reducing the burden of adverse outcome, before or during PCI. Although most of these agents have shown a remarkable effect on post-PCI CNRP incidence reduction, and it seems more powerful are still needed for a better validation of the results. It appears that intra lesion and distal intracoronary administrations would have a less systemic effect, and therefore may be safer than catheter injection. Moreover, adenosine, sodium nitroprusside, and calcium channel blockers are among the most routine- ly used methods. However, we believe that the best approach in treating or preventing no-reflow post-STMI might be combinational therapy. By the way, although there have been numerous studies on different agents capable of lessening the noreflow phenomenon, yet there is no exact guideline for choosing the most appropriate drug. A systematic review and meta-analysis on all available or practiced combinational pharmacotherapies to prevent PCI-related no-reflow are needed to suggest the most appropriate therapy.

Keywords

Open Access Policy: This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/

References

1. Danesh Sani SH, Eshraghi A, Shahri B, Vejdanparast M. No-reflow phenomenon in patients with STelevation acute myocardial infarction, treated with primary percutaneous coronary intervention: a study of predictive factors. Journal of Cardio-Thoracic Medicine. 2014; 2 (4):221-226

2. Assali AR, Sdringola S, Ghani M, Denkats AE, Yepes A, Hanna GP, Schroth G, Fujise K, Anderson HV, Smalling RW. Intracoronary adenosine administered during percutaneous intervention in acute myocardial infarction and reduction in the incidence of "no reflow" phenomenon. Catheterization and Cardiovascular interventions. 2000; 51 (1):27-31 https://doi.org/10.1002/1522-726X(200009)51:1<27::AID-CCD7>3.0.CO;2-0 PMid:10973014

3. Bouleti C, Mewton N, Germain S. The no-reflow phenomenon: state of the art. Archives of cardiovascular diseases. 2015; 108 (12):661-674 https://doi.org/10.1016/j.acvd.2015.09.006 PMid:26616729

4. Kloner RA. No-reflow phenomenon: maintaining vascular integrity. Journal of Cardiovascular Pharmacology and Therapeutics. 2011; 16 (3-4):244-250. https://doi.org/10.1177/1074248411405990 PMid:21821523

5. Rezkalla SH, Stankowski RV, Hanna J, Kloner RA. Management of no-reflow phenomenon in the catheterization laboratory. JACC: Cardiovascular Interventions. 2017; 10 (3):215-223. https://doi.org/10.1016/j.jcin.2016.11.059 PMid:28183461

6. Brosh D, Assali AR, Mager A, Porter A, Hasdai D, Teplitsky I, Rechavia E, Fuchs S, Battler A, Kornowski R. Effect of no-reflow during primary percutaneous coronary intervention for acute myocardial infarction on six-month mortality. American Journal of Cardiology. 2007; 99 (4):442-445 https://doi.org/10.1016/j.amjcard.2006.08.054 PMid:17293180

7. Born GVR. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature. 1962; 194 (4832):927-929 https://doi.org/10.1038/194927b0 PMid:13871375

8. Dhalla N, Pierce G, Panagia V, Singal P, Beamish R. Calcium movements in relation to heart function. Springer, 1982. https://doi.org/10.1007/BF01908167 PMid:6284117

9. Post R, Merritt C, Kinsolving C, Albright C. Membrane adenosine triphosphatase as a participant in the active transport of sodium and potassium in the human erythrocyte. J biol chem. 1960; 235:1796-1802 10. Paller MS, Hoidal J, Ferris TF. Oxygen free radicals in ischemic acute renal failure in the rat. The Journal of clinical investigation. 1984; 74 (4):1156-1164 https://doi.org/10.1172/JCI111524 PMid:6434591 PMCid:PMC425281

11. Barcin C, Denktas AE, Lennon RJ, Hammes L, Higano ST, Holmes DR, Garratt KN, Lerman A. Comparison of combination therapy of adenosine and nitroprusside with adenosine alone in the treatment of angiographic no‐ reflow phenomenon. Catheterization and cardiovascular interventions. 2004; 61 (4):484-491 https://doi.org/10.1002/ccd.20010 PMid:15065143

12. Galiuto L. Optimal therapeutic strategies in the setting of post-infarct no reflow: the need for a pathogenetic classification. Heart. 2004 Feb; 90(2): 123-125. https://doi.org/10.1136/hrt.2003.020800 PMid:14729769 PMCid:PMC1768057

13. Mahaffey KW, Puma JA, Barbagelata NA, DiCarli MF, Leesar MA, Browne KF, Eisenberg PR, Bolli R, Casas AC, Molina-Viamonte V. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial. Journal of the American College of Cardiology. 1999; 34 (6):1711-1720 https://doi.org/10.1016/S0735-1097(99)00418-0 PMid:10577561

14. Ross AM, Gibbons RJ, Stone GW, Kloner RA, Alexander RW, Investigators A-I. A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). Journal of the American College of Cardiology. 2005; 45 (11):1775-1780 https://doi.org/10.1016/j.jacc.2005.02.061 PMid:15936605

15. Braunwald E. Mechanism of action of calcium-channel-blocking agents. New England Journal of Medicine. 1982; 307 (26):1618-1627 https://doi.org/10.1056/NEJM198212233072605 PMid:6292718

16. Verdecchia P, Reboldi G, Angeli F, Gattobigio R, Bentivoglio M, Thijs L, Staessen JA, Porcellati C. Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension. 2005; 46 (2):386-392 https://doi.org/10.1161/01.HYP.0000174591.42889.a2 PMid:16009786

17. Reffelmann T, Hale SL, Li G, Kloner RA .Relationship between no reflow and infarct size as influenced by the duration of ischemia and reperfusion. American Journal of Physiology-Heart and Circulatory Physiology. 2002; 282 (2):H766-H772 https://doi.org/10.1152/ajpheart.00767.2001 PMid:11788428

18. Abbo KM, Dooris M, Glazier S, O'Neill WW, Byrd D, Grines CL, Safian RD. Features and outcome of no-reflow after percutaneous coronary intervention. The American journal of cardiology.1995; 75 (12):778-782 https://doi.org/10.1016/S0002-9149(99)80410-X PMid:7717278

19. Su Q, Li L, Liu Y. Short‐ term effect of verapamil on coronary no‐ reflow associated with percutaneous coronary intervention in patients with acute coronary syndrome: a systematic review and meta‐ analysis of randomized controlled trials. Clinical cardiology. 2013; 36 (8) https://doi.org/10.1002/clc.22143

20. Zhao J-L, Yang Y-J, Cui C-J, You S-J, Wu Y-J, Gao R-L. Different effects of adenosine and calcium channel blockade on myocardial no-reflow after acute myocardial infarction and reperfusion. Cardiovascular drugs and therapy. 2006; 20 (3):167-175 https://doi.org/10.1007/s10557-006-8284-9 PMid:16775665

21. Babbitt DG, Virmani R, Forman MB. Intracoronary adenosine administered after reperfusion limits vascular injury after prolonged ischemia in the canine model. Circulation. 1989; 80 (5):1388-1399 https://doi.org/10.1161/01.CIR.80.5.1388 PMid:2805274

22. Grossi L, D'Angelo S. Sodium nitroprusside: mechanism of NO release mediated by sulfhydrylcontaining molecules. Journal of medicinal chemistry. 2005; 48 (7):2622-2626 https://doi.org/10.1021/jm049857n PMid:15801852

23. Salvemini D, Currie MG, Mollace V. Nitric oxide-mediated cyclooxygenase activation. A key event in the antiplatelet effects of nitrovasodilators. The Journal of clinical investigation. 1996; 97 (11):2562-2568 https://doi.org/10.1172/JCI118704 PMid:8647949 PMCid:PMC507342

24. Massoudy P, Zahler S, Barankay A, Becker BF, Richter JA, Meisner H. Sodium nitroprusside during coronary artery bypass grafting: evidence for an antiinflammatory action. The Annals of thoracic surgery. 1999; 67 (4):1059-1064 https://doi.org/10.1016/S0003-4975(99)00157-5 PMid:10320251

25. Ignarro LJ, Lippton H, Edwards JC, Baricos WH, Hyman AL, Kadowitz PJ, Gruetter CA. Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: evidence for the involvement of S-nitrosothiols as active intermediates. Journal of Pharmacology and Experimental Therapeutics. 1981; 218 (3):739-749

26. Leone AM, Porto I, De Caterina AR, Basile E, Aurelio A, Gardi A, Russo D, Laezza D, Niccoli G, Burzotta F. Maximal hyperemia in the assessment of fractional flow reserve: intracoronary adenosine versus intracoronary sodium nitroprusside versus intravenous adenosine: the NASCI (Nitroprussiato versus Adenosina nelle Stenosi Coronariche Intermedie) study. JACC: Cardiovascular Interventions. 2012; 5 (4):402-408 https://doi.org/10.1016/j.jcin.2011.12.014 PMid:22516396

27. Benz S, Schnabel R, Weber H, Pfeffer F, Wiesner R, von Breitenbuch P, Nizze H, Schareck W, Hopt UT. THE NITRIC OXIDE DONOR SODIUM NITROPRUSSIDE IS PROTECTIVE IN ISCHEMIA/REPERFUSION INJURY OF THE PANCREAS1. Transplantation. 1998; 66 (8):994-999 https://doi.org/10.1097/00007890-199810270-00005 PMid:9808481

28. Berg R, Buhari C. Treating and preventing no reflow in the cardiac catheterization laboratory. Current cardiology reviews. 2012; 8 (3):209-214 https://doi.org/10.2174/157340312803217148 PMid:22920488 PMCid:PMC3465826

29. Wang HJ, Lo PH, Lin JJ, Lee H, Hung JS. Treatment of slow/no‐ reflow phenomenon with intracoronary nitroprusside injection in primary coronary intervention for acute myocardial infarction. Catheterization and cardiovascular interventions. 2004; 63 (2):171-176 https://doi.org/10.1002/ccd.20149 PMid:15390241

30. Kobatake R, Sato T, Fujiwara Y, Sunami H, Yoshioka R, Ikeda T, Saito H, Ujihira T. Comparison of the effects of nitroprusside versus nicorandil on the slow/no-reflow phenomenon during coronary interventions for acute myocardial infarction. Heart and vessels. 2011; 26 (4):379-384 https://doi.org/10.1007/s00380-010-0065-5 PMid:21110199

31. Parham WA, Bouhasin A, Ciaramita JP, Khoukaz S, Herrmann SC, Kern MJ. Coronary hyperemic dose responses of intracoronary sodium nitroprusside. Circulation. 2004; 109 (10):1236-1243 https://doi.org/10.1161/01.CIR.0000118470.52908.D9 PMid:14993141

32. Parikh KH, Chag MC, Shah KJ, Shah UG, Baxi HA, Chandarana AH, Naik AM, Shah JN, Shah HD, Goyal RK. Intracoronary boluses of adenosine and sodium nitroprusside in combination reverses slow/no-reflow during angioplasty: a clinical scenario of ischemic preconditioning. Canadian journal of physiology and pharmacology. 2007; 85 (3-4):476-482 https://doi.org/10.1139/Y07-013 PMid:17612657

33. Coller BS. Platelet GPIIb/IIIa antagonists: the first anti-integrin receptor therapeutics. The Journal of clinical investigation. 1997; 99 (7):1467-1471 https://doi.org/10.1172/JCI119307 PMid:9119988 PMCid:PMC507964

34. Eeckhout E, Kern M. The coronary no-reflow phenomenon: a review of mechanisms and therapies. European heart journal. 2001; 22 (9):729-739 https://doi.org/10.1053/euhj.2000.2172 PMid:11350105

35. Qin T, Xie L, Chen M-H. Meta-analysis of randomized controlled trials on the efficacy and safety of intracoronary administration of tirofiban for no-reflow phenomenon. BMC cardiovascular disorders. 2013; 13 (1):68 . https://doi.org/10.1186/1471-2261-13-68 PMid:24016038 PMCid:PMC3847195

36. Mak K-H . Recovery of coronary flow and left ventricular function after abciximab. Circulation. 1999; 100 (22):e110-e110 https://doi.org/10.1161/01.CIR.100.22.e110 PMid:10578011

37. Sun B, Liu Z, Yin H, Wang T, Chen T, Yang S, Jiang Z. Intralesional versus intracoronary administration of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention in patients with acute coronary syndromes: A meta-analysis of randomized controlled trials. Medicine 2017; 96 (40). https://doi.org/10.1097/MD.0000000000008223 PMid:28984776 PMCid:PMC5738012

38. Chiariello M, Gold HK, Leinbach RC, Davis MA, Maroko PR. Comparison between the effects of nitroprusside and nitroglycerin on ischemic injury during acute myocardial infarction. Circulation. 1976; 54 (5):766-773 https://doi.org/10.1161/01.CIR.54.5.766 PMid:824065

39. Sai S, Louie F, Sitaram S, Arunachalam V. Impact of intracoronary administration of nitroprusside vs. nitroglycerine before balloon dilatation on slow reflow during percutaneous coronary intervention in patients with acute ST elevation myocardial infarction. Cardiovascular Revascularization Medicine. 2011; 12 (3):e15-e16 https://doi.org/10.1016/j.carrev.2011.04.284

40. Kaumann A, Lemoine H. β 2-Adrenoceptor-mediated positive inotropic effect of adrenaline in human ventricular myocardium. Naunyn-Schmiedeberg's archives of pharmacology. 1987; 335 (4):403-411. https://doi.org/10.1007/BF00165555 PMid:2885760

41. Sato T, Sasaki N, O'Rourke B, Marbán E. Nicorandil, a potent cardioprotective agent, acts by opening mitochondrial ATP-dependent potassium channels. Journal of the American College of Cardiology. 2000; 35 (2):514- 518 https://doi.org/10.1016/S0735-1097(99)00552-5 PMid:10676702

42. Cahoon NJ. Efficacy and mechanism of nicorandil in perioperative protection of skeletal muscle from ischaemia and reperfusion injury in a porcine model. University of Glasgow. 2012. In available: https://eleanor.lib.gla.ac.uk/record=b2979529

43. Ito H, Taniyama Y, Iwakura K, Nishikawa N, Masuyama T, Kuzuya T, Hori M, Higashino Y, Fujii K, Minamino T. Intravenous nicorandil can preserve microvascular integrity and myocardial viability in patients with reperfused anterior wall myocardial infarction. Journal of the American College of Cardiology. 1999; 33 (3):654-660 https://doi.org/10.1016/S0735-1097(98)00604-4 PMid:10080465

44. Ishii H, Ichimiya S, Kanashiro M, Amano T, Imai K, Murohara T, Matsubara T. Impact of a Single Intravenous Administration of Nicorandil Before Reperfusion in Patients With ST-Segment-Elevation Myocardial Infarction. Circulation.2005; 112 (9):1284-1288 https://doi.org/10.1161/CIRCULATIONAHA.104.530329 PMid:16116055

45. Lim SY, Bae EH, Jeong MH, Kang DG, Lee YS, Kim KH, Lee SH, Yoon KH, Hong SN, Park HW. Effect of combined intracoronary adenosine and nicorandil on no-reflow phenomenon during percutaneous coronary intervention. Circulation Journal. 2004; 68 (10):928-932 https://doi.org/10.1253/circj.68.928 PMid:15459466

46. Mizumura T, Nithipatikom K, Gross GJ. Infarct size-reducing effect of nicorandil is mediated by the KATP channel but not by its nitrate-like properties in dogs. Cardiovascular research. 1996; 32 (2):274-285 47. Tsubokawa A, Ueda K, Sakamoto H, Iwase T, Tamaki S-i. Effect of intracoronary nicorandil administration on preventing no-reflow/slow flow phenomenon during rotational atherectomy. Circulation journal. 2002; 66 (12):1119-1123 https://doi.org/10.1253/circj.66.1119 PMid:12499617

48. Piot C, Croisille P, Staat P, Thibault H, Rioufol G, Mewton N, Elbelghiti R, Cung TT, Bonnefoy E, Angoulvant D. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. New England Journal of Medicine. 2008; 359 (5):473-481 https://doi.org/10.1056/NEJMoa071142 PMid:18669426

49. Kucukcelebi A, Ozcan M. The beneficial effect of cyclosporin-A on the no-reflow phenomenon in rat skin island flaps. British journal of plastic surgery. 1992; 45 (7):512-514 https://doi.org/10.1016/0007-1226(92)90144-M PMid:1446193

50. Stangier J, Rathgen K, Stähle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. British journal of clinical pharmacology. 22007; 64 (3):292-303 https://doi.org/10.1111/j.1365-2125.2007.02899.x PMid:17506785 PMCid:PMC2000643

51. Spagnoli V, Klein E, Sideris G, Magkoutis N, Brumpt C, Bal Dit Sollier C, Henry P, Drouet L. Correlation between burst of thrombin and microvacular obstruction (no reflow) during ST Elevation Myocardial Infarction treated by primary percutaneous coronary Intervention. European Heart Journal. 2013; 34 (suppl_1):1608 https://doi.org/10.1093/eurheartj/eht308.1608

52. Hale SL, Kloner RA. Dabigatran treatment: effects on infarct size and the no-reflow phenomenon in a model of acute myocardial ischemia/reperfusion. Journal of thrombosis and thrombolysis. 2015; 39 (1):50-54 https://doi.org/10.1007/s11239-014-1098-x PMid:25017632

53. Nauck MA, Meier JJ. Glucagon-like peptide 1 and its derivatives in the treatment of diabetes. Regulatory peptides. 2005; 128 (2):135-148 https://doi.org/10.1016/j.regpep.2004.07.014 PMid:15780433

54. Chen WR, Tian F, Dai Chen Y, Wang J, Yang JJ, Wang ZF, Da Wang J, Ning QX. Effects of liraglutide on no-reflow in patients with acute ST-segment elevation myocardial infarction. International journal of cardiology. 2016; 208:109-114 https://doi.org/10.1016/j.ijcard.2015.12.009 PMid:26849684

55. Poupko JM, Baskin SI, Moore E. The pharmacological properties of anisodamine. Journal of Applied Toxicology. 2007; 27 (2):116-121 https://doi.org/10.1002/jat.1154 PMid:17186568

56. Niu X, Zhang J, Bai M, Peng Y, Sun S, Zhang Z. Effect of intracoronary agents on the no-reflow phenomenon during primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction: a network meta-analysis. BMC cardiovascular disorders. 2018; 18 (1):3 https://doi.org/10.1186/s12872-017-0722-z PMid:29320987 PMCid:PMC5763527

57. Jun W, FAN G, Yunfa WJ. Effect of intracoronary administration of anisodamine on slow reflow phenomenon following primary percutaneous coronary intervention in patients with acute myocardial infarction [J]. Journal of Clinical Cardiology. 2006; 1:008

58. Poeggeler B, Saarela S, Reiter RJ, TAN DX, CHEN LD, Manchester LC, BARLOW‐ WALDEN LR. Melatonin-a highly potent endogenous radical scavenger and electron donor: new aspects of the oxidation chemistry of this indole accessed in vitro. Annals of the New York Academy of Sciences. 1994; 738 (1):419-420 https://doi.org/10.1111/j.1749-6632.1994.tb21831.x PMid:7832450

59. Zhou H, Ma Q, Zhu P, Ren J, Reiter RJ, Chen Y . Protective role of melatonin in cardiac ischemia‐ reperfusion injury: from pathogenesis to targeted therapy. Journal of pineal research. 2018; 64(3). https://doi.org/10.1111/jpi.12471 PMid:29363153

60. Reiter RJ, Tan D-X. Melatonin: a novel protective agent against oxidative injury of the ischemic/reperfused heart. Cardiovascular research. 2003; 58 (1):10-19 https://doi.org/10.1016/S0008-6363(02)00827-1 PMid:12667942

61. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial- Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. The Lancet. 2003; 361 (9364):1149- 1158 https://doi.org/10.1016/S0140-6736(03)12948-0 PMid:12686036

62. Liu W, Zou Z, Jiang H, Li Q, Guo F, Wang Z, Zhu H. Clinical effect of preoperative high-dose atorvastatin against no-reflow after PCI. Experimental and therapeutic medicine. 2017; 13 (1):97-102 https://doi.org/10.3892/etm.2016.3910 PMid:28123475 PMCid:PMC5244837

63. BriguoriC C, Visconti G, Focaccio A, Golia B, Chieffo A, Casteli A, et al. Novel approaches for preventing or limiting events (Naples) II trial: impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction. J Am Coll Cardiol. 2009 Dec 1;54(23):2157-63.

64. Eshraghi A, Talasaz AH, Salamzadeh J, Salarifar M, Pourhosseini H, Nozari Y, Bahremand M, Jalali A, Boroumand MA . Evaluating the effect of intracoronary N-acetylcysteine on platelet activation markers after primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction. American journal of therapeutics. 2016; 23 (1):e44-e51 https://doi.org/10.1097/MJT.0000000000000309 PMid:26291594

65. Andrews NP, Prasad A, Quyyumi AA. N-acetylcysteine improves coronary and peripheral vascular function. Journal of the American College of Cardiology. 2001; 37 (1):117-123 https://doi.org/10.1016/S0735-1097(00)01093-7 PMid:11153725

66. Weinbroum AA, Kluger Y, Abraham RB, Shapira I, Karchevski E, Rudick V. LUNG PRECONDITIONING WITH N-ACETYL-l-CYSTEINE PREVENTS REPERFUSION INJURY AFTER LIVER NO FLOW-REFLOW: A DOSE-RESPONSE STUDY1. Transplantation 2001; 71 (2):300-306 https://doi.org/10.1097/00007890-200101270-00023 PMid:11213077

Razavi International Journal of Medicine

Article View: 374
PDF Download: 263

Coronary No-reflow Phenomenon: A Review of Therapeutic Pharmacological Agents

References

Volume 8, Issue 1234
October 2020
Pages 1-7

Files

Share

How to cite

Statistics

Coronary No-reflow Phenomenon: A Review of Therapeutic Pharmacological Agents

References

Volume 8, Issue 1234October 2020Pages 1-7

Files

Share

How to cite

Statistics

Volume 8, Issue 1234
October 2020
Pages 1-7